---
title: "Materialise posts Q1 2026 profit as medical segment and margin gains offset revenue headwinds"
url: https://www.voxelmatters.com/materialise-posts-q1-2026-profit-as-medical-segment-and-margin-gains-offset-revenue-headwinds/
date: 2026-05-07
modified: 2026-05-07
lang: en
author: "Joseph Caron-Dawe"
description: "Materialise recorded a net profit of €1.82 million ($2.14m) in the first quarter of 2026, reversing a net loss of €535,000 ($630,000) in the same period a year earlier. Total..."
categories:
  - "3D Printing Service Providers"
  - "Financial Reports"
  - "Money & Funding"
tags:
  - "insights"
image: https://www.voxelmatters.com/wp-content/uploads/2022/09/20170921_materialise_193-640x427.jpg
word_count: 451
---

# Materialise posts Q1 2026 profit as medical segment and margin gains offset revenue headwinds

[Materialise](https://www.voxelmatters.directory/company/materialise/) recorded a net profit of €1.82 million ($2.14m) in the first quarter of 2026, reversing a net loss of €535,000 ($630,000) in the same period a year earlier. Total revenue held essentially flat at €66.28m ($78.05m), compared with €66.38m ($78.17m) in Q1 2025.

Gross profit rose 3.2% to €37.89m ($44.62m), as adjusted earnings before interest and taxes (EBIT) climbed to €2.47m ($2.91m) from €646,000 ($760,000), with the adjusted EBIT margin expanding to 3.7% from 1.0%.

The software and service provider – which trades on the NASDAQ – saw its net cash position grow by €2.02m ($2.38m) over the quarter to €72.83m ($85.72m), while €2.31m ($2.72m) was directed toward share buybacks.

“In a quarter where elevated geopolitical uncertainty and unfavorable foreign currency exchange movements weighed on our revenue growth, [we improved operational profitability across all business segments through operational focus and continued cost control](https://www.voxelmatters.com/materialise-reports-2025-q4-revenue-growth-of-6-8/),” stated Brigitte de Vet-Veithen, Chief Executive Officer of Materialise.

![](https://www.voxelmatters.com/wp-content/uploads/2024/02/og-brigitte-de-vet-veithen-e1771500213242-340x316.jpg)Materialise CEO Brigitte de Vet-Veithen.

“We closed the quarter with positive operating and free cash flow and a further improved net cash position, reinforcing the strength of our balance sheet and providing us with the flexibility to [continue investing in innovation and growth](https://www.voxelmatters.com/learn-about-the-materialise-2026-outlook-from-ceo-brigitte-de-vet/).”

## Segment performance

The Materialise Medical segment led the three divisions, with revenue up 6.7% to €33.17m ($39.01m). The Software segment posted a 1.4% revenue decline to €9.64m ($11.36m), though its adjusted EBITDA margin expanded sharply to 11.6% from 6.1%. 

The Manufacturing segment saw revenue fall 8.1% to €23.47m ($27.64m), but returned to positive adjusted EBITDA of €281,000 ($331,000) after recording a loss of €377,000 ($444,000) in Q1 2025.

## Eyewear transfer and full-year guidance

Materialise separately reached an agreement to transfer its eyewear business to the unit's management team, following the sale of its Rapidfit business at the end of March 2026. The company will retain a minority stake in the newly formed eyewear entity. Impairment charges related to the transaction are expected in Q2 2026.

On full-year guidance, de Vet-Veithen stated: “As previously communicated in our guidance issued in February, we expect macro‑economic and geopolitical uncertainty to persist throughout fiscal year 2026. Nevertheless, we continue to have confidence in the strength and resilience of our underlying business fundamentals.

“The strategic repositioning initiatives and targeted investments across our three business segments are expected to progressively support operational performance and profitable growth. [Notwithstanding the anticipated impact of the divestments of Rapidfit](https://www.voxelmatters.com/materialise-to-spin-off-rapidfit-business-in-management-led-transfer/) and Eyewear, we reaffirm our full‑year revenue guidance for fiscal year 2026 in the range of €273m ($321.5m) to €283m ($333.2m).

“In addition, we are maintaining our Adjusted EBIT guidance for fiscal year 2026 of $10m ($11.78m) to $12m ($14.1m), reflecting our continued focus on execution discipline, cost management, and capital allocation.”